InVivoMab anti-mouse CD8β (Lyt 3.2) BE0223-R005mg from Bio X Cell

Description

Bio X Cell InVivoMAb anti-mouse CD8β (Lyt 3.2) Monoclonal Antibody has the following reported applications: in vivo CD8+ T cell depletion, in vitro CD8 blockade, Immunofluorescence. It features greater than 95% purity, ultra-low endotoxin levels, and are preservative, stabilizer, and carrier protein-free

Product Specs
ItemInVivoMab anti-mouse CD8β (Lyt 3.2)
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0223-R005mg
Quantity5 mg
Applicationsin vivo CD8+ T cell depletion, in vitro CD8 blockade, Immunofluorescence
ConcentrationLot specific,typically between 4-11 mg/ml
Conjugate/TagUnconjugated
ReactivityMouse
TargetCD8 beta
IsotypeIgG1, κ
Clone53-5.8
Hostrat
NCBI Full Gene NameCD8 subunit beta 1
NCBI Gene AliasesCd8b, Ly-3, Ly-C, Lyt-3
ClonalityMonoclonal
ImmunogenMouse thymus or spleen
Antibody TypePrimary Antibody
Purity>95%, Determined by SDS-PAGE
FormatPBS, pH 7.0, Contains no stabilizers or preservatives
Research AreaImmunology

Specifications/Features

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

Add to Compare List

Bio X Cell

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

Company Profile

Website: bioxcell.com

(1) Activated Brain Endothelial Cells Cross-Present Malaria AntigenPLoS pathogensJune 1, 2015Howland SW, Poh CM, Rénia L.

(2) Immunosurveillance and therapy of multiple myeloma are CD226 dependentThe Journal of clinical investigationMay 1, 2015Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow SF, Yong MC, Teng MW, Colonna M, Ritchie DS, Chesi M, et al.

(3) NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphomaOncoimmunologyMarch 1, 2015Kobayashi T, Doff BL, Rearden RC, Leggatt GR, Mattarollo SR.

(4) Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbsClinical cancer research : an official journal of the American Association for Cancer ResearchOctober 15, 2013Allard B, Pommey S, Smyth MJ, Stagg J.

(5) Direct in vivo evidence of CD4+ T cell requirement for CTL response and memory via pMHC-I targeting and CD40L signalingJournal of leukocyte biologyAugust 1, 2012Ahmed KA, Wang L, Munegowda MA, Mulligan SJ, Gordon JR, Griebel P, Xiang J.

(6) Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodiesCancer researchJuly 1, 2012Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, Duret H, Yagita H, Johnstone RW, Smyth MJ, et al.

(7) Self-class I MHC molecules support survival of naive CD8 T cells, but depress their functional sensitivity through regulation of CD8 expression levelsThe Journal of experimental medicineSeptember 28, 2009Takada K, Jameson SC.

Be the First to Write a Review!